1-4 of 4
Jia Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study

Alison M Schram, Vivek Subbiah, Chih-Yi (Andy) Liao, Victor Moreno, Roda Desamparados, Mariano Ponz-Sarvise, Efrat Dotan, Philippe Alexandre Cassier, Irene Moreno, Andreas Varkaris, Richard D Kim, Elena Garralda, Frans Opdam, David Tai, Antoine Italiano, Do-Youn Oh, Lipika Goyal, Elisa Fontana, Jia Liu, Myrto Boukovala, Francois Ghiringelli, Mitesh J Borad, Hani Babiker, Zhaohui Jin, Michael Millward, Jeffrey Yachnin, Suneel Deepak Kamath, Jermaine M. Coward, Changhoon Yoo, Robin Kate Kelley, Vaibhav Sahai, John Bridgewater, Christoph Springfield, Vaia Florou, Anthony El-Khoueiry, Ferry Eskens, Bruce Lin, Scott Paulson, Giuseppe Curigliano, Meredith Murphy, Alicia Deary, Fabien Ricard, Kai Yu Jen, Florence (Tianhui) Ramirez, Rick E. Blakesley, Oleg Schmidt-Kittler, Brenton G. Mar, Joon Oh Park, Antoine Hollebecque
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): IA006.
https://doi.org/10.1158/1535-7163.TARG-23-IA006
Published: 01 December 2023
View article titled, Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
Journal Articles

Abstract B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111/DEP irinotecan) in patients with advanced solid tumours

Jia Liu, Anna R Minchom, Alastair Greystoke, Thomas R J Evans, Debashis Sarker, Anthony M Joshua, Cienne Morton, Aisha Gaus, Wing Yau, Rasha Cosman, Dominika Chwialkowska, Jeremy R A Paull, Bernadette M Jean-Francois, Jacinth K Fairley, Nicola J Main, Stephanie R Edmondson, Natalie Cook
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B039.
https://doi.org/10.1158/1535-7163.TARG-23-B039
Published: 01 December 2023
View article titled, Abstract B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111/DEP irinotecan) in patients with advanced solid tumours
Journal Articles

AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients

Xiao Xu, Long Mao, Wanhong Xu, Wei Tang, Xiaoying Zhang, Biao Xi, Rongda Xu, Xin Fang, Jia Liu, Ce Fang, Li Zhao, Xiaobo Wang, Ji Jiang, Pei Hu, Hongyun Zhao, Li Zhang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (11): 2586–2597.
https://doi.org/10.1158/1535-7163.MCT-16-0281
Published: 01 November 2016
View article titled, AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
Open the PDF for AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Identification of LIV1, a Putative Zinc Transporter Gene Responsible for HDACi-Induced Apoptosis, Using a Functional Gene Screen Approach

Xiaoli Ma, Quanfu Ma, Jia Liu, Yuan Tian, Beibei Wang, Kathryn M. Taylor, Peng Wu, Daowen Wang, Gang Xu, Li Meng, Shixuan Wang, Ding Ma, Jianfeng Zhou
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (11): 3108–3116.
https://doi.org/10.1158/1535-7163.MCT-08-0772
Published: 10 November 2009
View article titled, Identification of <em>LIV1</em>, a Putative Zinc Transporter Gene Responsible for HDACi-Induced Apoptosis, Using a Functional Gene Screen Approach
Open the PDF for Identification of <em>LIV1</em>, a Putative Zinc Transporter Gene Responsible for HDACi-Induced Apoptosis, Using a Functional Gene Screen Approach in another window
Includes: Supplementary data